URI
65
5
CPB
30
6
BA
54
5
UA
50
-9
HST
49
-9
MA
64
7
RL
72
4
FTI
81
5
LMT
34
2
ACN
52
3
HON
67
2
IBM
58
-2
EBAY
47
4
EMN
60
4
GS
75
2
PPL
54
-5
ROST
63
12
PSA
58
2
WM
79
3
NOC
43
11
URI
65
5
CPB
30
6
BA
54
5
UA
50
-9
HST
49
-9
MA
64
7
RL
72
4
FTI
81
5
LMT
34
2
ACN
52
3
HON
67
2
IBM
58
-2
EBAY
47
4
EMN
60
4
GS
75
2
PPL
54
-5
ROST
63
12
PSA
58
2
WM
79
3
NOC
43
11
Financhill
Back

uniQure NV 10K Form

Sell
23

QURE
uniQure NV

Last Price:
5.78
Seasonality Move:
7.28%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive QURE News And Ratings

See the #1 stock for the next 7 days that we like better than QURE

QURE Financial Statistics

Sales & Book Value

Annual Sales: $15.84M
Cash Flow: $-45.28M
Price / Cash Flow: 0
Annual Sales: $1.15
Price / Book: 5.05

Profitability

EPS (TTM): -4.96000
Net Income (TTM): $-239.5M
Gross Margin: $2.22M
Return on Equity: -154.29%
Return on Assets: -31.11%

uniQure NV Earnings Forecast

Key uniQure NV Financial Ratios

  • The Gross Profit Margin over the past 11 years for QURE is 13.98%.
  • The Selling, General & Administrative Expenses for QURE have been equal to 470.81% of Gross Profit Margin.
  • The Research & Development expenses have been 1,356.21% of Revenue.
  • The Interest Expense is -13.47% of Operating Income.
  • The Net Earning history of QURE is -1,947.09% of Total Revenues.
  • Per Share Earnings over the last 13 years have been positive in 5 years.

uniQure NV Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: QURE
CUSIP: N90064
Website: uniqure.com

Debt

Debt-to-Equity Ratio: 0.92
Current Ratio: 6.51
Quick Ratio: 6.18

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

QURE Technical Analysis vs Fundamental Analysis

Sell
23
uniQure NV (QURE) is a Sell

Is uniQure NV a Buy or a Sell?

  • uniQure NV stock is rated a Sell
    The current uniQure NV [QURE] share price is $5.78. The Score for QURE is 23, which is 54% below its historic median score of 50, and infers higher risk than normal.